Global Fund appoints new board heads

The Global Fund to Fight AIDS, Tuberculosis and Malaria has appointed Tedros Adhanom Ghebreyesus as board chair and Dr Ernest Loevinsohn as vice-chair. Tedros Adhanom Ghebreyesus Mr Ghebreyesus has been minister of health of Ethiopia since 2005. He served as chair of the Roll Back Malaria Partnership until May this year, and continues to head the UNAIDS programme co-ordination board. He has also held various roles in advisory groups such as the executive committee of the Partners in Population and Development and the GAVI Alliance. He succeeds Rajat Guptas, partner and former managing director of McKinsey & Company, as board chair. Dr Ernest Loevinsohn Vice-chair Dr Loevinsohn is director general of the Global Initiatives Directorate in the Canadian International Development Agency (CIDA). He was founding chair of the Global Stop TB Partnership, and continues to represent Canada, Germany and Switzerland on the board of the Global Fund. In his vice-chair role he replaces Elizabeth Mataka, executive director of the Zambia National AIDS Network. Both will chair their first board meeting in November.

The Global Fund to Fight AIDS, Tuberculosis and Malaria has appointed Tedros Adhanom Ghebreyesus as board chair and Dr Ernest Loevinsohn as vice-chair.

Tedros Adhanom Ghebreyesus

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anti-infective

Scrip Data Article Without An Author

"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."

In Brief: PolyPid’s D-PLEX100 Aces Phase III Trial, US Partner, Submission Eyed

PolyPid's D-PLEX100 meets Phase III endpoints this time around, significantly reducing surgical point infections in abdominal colorectal surgery, and is set for a US approval submission early next year.

Bavarian Nordic Well Placed To Meet Mpox Vaccine Demand

 

The company will ramp up manufacturing of its Jynneos vaccine to meet demand in worst-affected African countries and stockpiling richer nations.  

Cagrisema Leads The Charge For 2025

 

2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.  

More from Therapeutic Category

Scrip Data Article Without An Author

"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.